Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Rectal PC-1005 Gel in HIV-Negative Adults
NCT03408899Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2018
- Primary completion
- Apr 2019
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PC-1005 in human immunodeficiency virus infection (HIV), human papillomavirus infection and herpes simplex virus infection, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Frequency of Grade 2 or Higher Adverse Events, MIV-150 Concentrations in Plasma and 2 more. Started Jun 2018; status: completed.
02
Drugs
PC-1005
03
Conditions
human immunodeficiency virus infection (HIV)human papillomavirus infectionherpes simplex virus infection
Beyond the preview
Go deeper on NCT03408899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03408899.